Overview

Crosstree Capital Partners is pleased to announce the acquisition of specialist blood coagulation clinical diagnostic reagents company, American Diagnostics, Inc. by Sekisui Chemical Co., Ltd. (TSE: 4204).

American Diagnostica is a developer, manufacturer and distributor of an extensive range of clinical diagnostic and research products targeting the fields of coagulation, fibrinolysis, thrombosis, hemostasis and oncology.

Significance

The acquisition provides Sekisui Medical Co., Ltd., a subsidiary of Sekisui Chemical Co., Ltd., with a robust, complementary product line, a well-established international customer base, a geographic presence in the US, Canada and Germany and significant North American and European regulatory experience.

Leveraging the complementary strengths of the respective enterprises, Sekisui Medical intends to build market share globally.

Crosstree’s Role

Crosstree Capital Partners was the exclusive financial advisor to American Diagnostica, Inc. in the transaction.

Crosstree conducted a broad, yet targeted, global sale process.

Crosstree identified Sekisui, a relatively unknown player in the US market at the time with no diagnostic presence, initiated the transaction and successfully managed the negotiations and closing process.